COVID-19 Clinical Rebound After Treatment With Nirmatrelvir-Ritonavir Is Generally Mild With Favorable Outcomes, Research Finds

Infectious Disease Advisor (10/29, Kuhns) reports research found that “COVID-19 clinical rebound after treatment with nirmatrelvir-ritonavir (Paxlovid) may be more common than previously reported, but symptoms are generally mild and most outcomes are favorable.” The investigators said, “COVID-19 viral and/or symptom rebound is more likely to occur among those who fail to adequately clear SARS-CoV-2 virus in the upper respiratory tract in a dynamic process.” The findings were published in BMC Infectious Diseases.